Arcutis Biotherapeutics, Inc.ARQTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 83% recommend buying.

Consensus Rating

Buy

12 analysts·Moderate coverage

83%

Rating Distribution

Strong Buy

00%

Buy

1083%

Hold

217%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 26% higher.

Bear Case

$29.00

+14%

Consensus

$32.00

+26%

Bull Case

$37.00

+46%

Price Range12 analysts

Low

Consensus

High

$29.00

$37.00

Current Target

Current Price

$25.37

Upside to Target

$6.63

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$0.46(5 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+30.59%

EPS+193.85%

FY2028

Rev+25.56%

EPS+62.83%

FY2029

Rev+18.33%

EPS+36.30%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+30.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Nov 28, 2025Mizuho Securities

Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $37 at Mizuho

Target:$37.00

+19.5%from $30.96

Oct 30, 2025Goldman Sachs

Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs

Target:$29.00

+14.1%from $25.41

Oct 29, 2025H.C. Wainwright

Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright

Target:$30.00

+20.2%from $24.95

Oct 29, 2025Mizuho Securities

Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $32 at Mizuho

Target:$32.00

+28.3%from $24.95

Mar 11, 2025Jefferies

Arcutis Biotherapeutics price target raised to $19 from $16 at Jefferies

Target:$19.00

+22.7%from $15.49

Dec 30, 2024H.C. Wainwright

Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright

Target:$19.00

+33.8%from $14.20

May 15, 2024Needham

Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Needham

Target:$18.00

+121.4%from $8.13

May 15, 2024Mizuho Securities

Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho

Target:$18.00

+121.4%from $8.13

Jan 2, 2024Mizuho Securities

Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $8 at Mizuho Securities, Upgraded to Buy

Target:$8.00

+133.2%from $3.43

Dec 13, 2022Morgan Stanley

Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $51

Target:$51.00

+207.6%from $16.58

Apr 27, 2022Goldman Sachs

Goldman Sachs Bullish on These 3 Stocks for Triple-Digit Returns

Target:$37.00

+88.6%from $19.61

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance